| PERIOD ENDING | 30-Sep-09 | 30-Jun-09 | 31-Mar-09 | 31-Dec-08 | | Total Revenue | 275,772 | 278,521 | 253,518 | 292,398 | | Cost of Revenue | 160,299 | 161,241 | 158,008 | 183,535 | | | Gross Profit | 115,473 | 117,280 | 95,510 | 108,863 | | | Operating Expenses | | Research Development | 30,909 | 30,143 | 28,395 | 29,285 | | Selling General and Administrative | 36,311 | 39,128 | 35,343 | 36,957 | | Non Recurring | 73 | 592 | 120 | 209,726 | | Others | 9,281 | 9,263 | 9,263 | 9,341 | | | | Total Operating Expenses | 76,574 | 79,126 | 73,121 | 285,309 | | | | Operating Income or Loss | 38,899 | 38,154 | 22,389 | (176,446) | | | Income from Continuing Operations | | Total Other Income/Expenses Net | (189) | (173) | 3,384 | 1,990 | | Earnings Before Interest And Taxes | 38,710 | 37,981 | 25,773 | (174,456) | | Interest Expense | 4,356 | 4,278 | 4,487 | 1,776 | | Income Before Tax | 34,354 | 33,703 | 21,286 | (176,232) | | Income Tax Expense | 12,655 | 10,794 | 8,404 | (14,176) | | Minority Interest |
-
|
-
|
-
|
-
| | | | Net Income From Continuing Ops | 21,699 | 22,909 | 12,882 | (162,056) | | | Non-recurring Events | | Discontinued Operations |
-
|
-
|
-
|
-
| | Extraordinary Items |
-
|
-
|
-
|
-
| | Effect Of Accounting Changes |
-
|
-
|
-
|
-
| | Other Items |
-
|
-
|
-
|
-
| | | | Net Income | 21,699 | 22,909 | 12,882 | (162,056) | | Preferred Stock And Other Adjustments |
-
|
-
|
-
|
-
| | | Net Income Applicable To Common Shares | $21,699 | $22,909 | $12,882 | ($162,056) |
|
1.52% Nasdaq 
Income Statement
